Thomson Horstmann & Bryant Inc. raised its holdings in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 10.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 356,517 shares of the medical instruments supplier’s stock after purchasing an additional 34,162 shares during the period. LeMaitre Vascular comprises about 1.5% of Thomson Horstmann & Bryant Inc.’s portfolio, making the stock its 13th largest holding. Thomson Horstmann & Bryant Inc. owned approximately 1.85% of LeMaitre Vascular worth $11,351,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the business. BNP Paribas Arbitrage SA grew its position in shares of LeMaitre Vascular by 11,612.5% during the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 3,716 shares during the last quarter. Teachers Retirement System of The State of Kentucky bought a new position in shares of LeMaitre Vascular during the second quarter worth about $137,000. Victory Capital Management Inc. grew its position in shares of LeMaitre Vascular by 181.2% during the third quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock worth $155,000 after acquiring an additional 2,667 shares during the last quarter. Royce & Associates LP bought a new position in shares of LeMaitre Vascular during the second quarter worth about $156,000. Finally, Royal Bank of Canada lifted its holdings in LeMaitre Vascular by 856.5% in the second quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 4,505 shares during the period. Hedge funds and other institutional investors own 69.24% of the company’s stock.
In related news, insider David B. Roberts sold 4,123 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $32.14, for a total value of $132,513.22. Following the transaction, the insider now owns 24,482 shares in the company, valued at $786,851.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 23.70% of the company’s stock.
Several research firms recently weighed in on LMAT. Canaccord Genuity reaffirmed a “hold” rating and issued a $30.00 price objective on shares of LeMaitre Vascular in a report on Monday, October 9th. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday, September 28th. Benchmark lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. First Analysis lowered shares of LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 price objective for the company. in a research note on Friday, October 27th. Finally, BidaskClub lowered shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $32.20.
Shares of LeMaitre Vascular Inc (LMAT) traded up $0.10 on Wednesday, hitting $32.84. The stock had a trading volume of 70,911 shares, compared to its average volume of 124,600. The firm has a market cap of $628.81, a P/E ratio of 42.65, a price-to-earnings-growth ratio of 2.51 and a beta of 0.54. LeMaitre Vascular Inc has a one year low of $19.82 and a one year high of $39.88.
LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.05. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The company had revenue of $24.80 million for the quarter, compared to the consensus estimate of $25.49 million. During the same quarter in the prior year, the company earned $0.17 EPS. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. analysts anticipate that LeMaitre Vascular Inc will post 0.84 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “LeMaitre Vascular Inc (LMAT) Holdings Raised by Thomson Horstmann & Bryant Inc.” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/17/thomson-horstmann-bryant-inc-has-11-35-million-holdings-in-lemaitre-vascular-inc-lmat.html.
LeMaitre Vascular Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.